Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

p21(WAF1) expression and endocrine response in breast cancer

McClelland, Richard Andrew, Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015, O'Sullivan, Louise A., Barnes, D. M., Robertson, J. F. R., Ellis, I. O. and Nicholson, Robert Ian 1999. p21(WAF1) expression and endocrine response in breast cancer. Journal of Pathology 188 (2) , pp. 126-132. 10.1002/(SICI)1096-9896(199906)188:2<126::AID-PATH340>3.0.CO;2-O

Full text not available from this repository.

Abstract

An immunocytochemical assay for the p53-regulated protein product of the WAF1/Cip1 gene, p21WAF1 (p21), was developed and applied to archival primary breast tumour material from 91 patients whose subsequent recurrent disease was treated with assessable courses of endocrine therapy. Nuclear localization of p21 protein was observed in 76 (82·4 per cent) cases. Status cut-offs were established and 29 (31·9 per cent) were deemed negative, 39 (42·9 per cent) weakly positive, and 23 (25·3 per cent) strongly positive. p21 status was inversely correlated with p53 protein (p = 0·047) but did not relate to oestrogen receptor (ER) status, response to endocrine therapy, or time to further disease progression (TTP). Highly p21-positive patients had a significantly improved overall survival time (p = 0·020). Co-assessment of p21 and p53 subgroups revealed p21 + /p53 − patients to have good survival characteristics, whilst p21 − /p53+ patients did poorly (p = 0·008). The p21 − /p53− patients overall did intermediately well, but Ki67-defined cellular proliferation analysis of these revealed two subclasses: those with high proliferation and poor survival times resembling the p21 − /p53+ phenotype, and those with less proliferative tumours with good survival, similar to the p21 + /p53− group. The significance of these results is discussed in the light of recent research concerning the role of p21 and p53 in breast cancer aetiology.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Medicine
Biosciences
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords: p53; tumour suppressor genes; breast cancer; p21; endocrine response; prognosis
Publisher: Wiley-Blackwell
ISSN: 1096-9896
Last Modified: 18 Oct 2022 14:20
URI: https://orca.cardiff.ac.uk/id/eprint/17161

Citation Data

Cited 29 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item